Use of il-1beta binding antibodies
AssigneeNovartis AG
InventorsAndreas BRUEDERLE, Anshu MARATHE, Jean REGARD, Mikael RINNE, Haiying SUN, K. Gary J. VANASSE, Connie WONG
Life of this patent
Estimating the term…
Abstract
Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.
Claims22
1-53. (canceled)
A method of treating or preventing one or more myelodysplastic syndromes (MDS) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an IL-1β binding antibody, or functional fragment thereof.
A method of treating one or more MDS in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an IL-1β binding antibody, or a functional fragment thereof, in combination with a therapeutically effective amount of a TIM-3 binding antibody, or a functional fragment thereof.
A method of treating one or more low risk MDS, as defined by IPSS-R, in a subject in need thereof, comprising
- a) administering canakinumab, or a functional fragment thereof, at a dose of 200 mg every 3 weeks in combination with MBG453, or a functional fragment thereof, at a dose of 600 mg every 3 weeks;
- or
- b) administering canakinumab, or a functional fragment thereof, at a dose of 250 mg every 4 weeks in combination with MBG453, or a functional fragment thereof, at a dose of 800 mg every 4 weeks.
Dependencies are inferred from the claim text.